TIGIT and plasma cell myeloma: Studies involving TIGIT-deficient models have highlighted its vital role in cancer progression, with reduced tumor growth in TIGIT-deficient mice compared to normal counterparts, especially in breast and colon cancers, along with a notable increase in survival rates in myeloma models and protection against experimental lung metastasis.